liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Regulatorik [Regulatory issues]: neue Endpunkte in chronische Nierenerkrankungs(CKD)-Studien [new endpoints in chronic kidney disease (CKD) studies]
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Diagnostics and Specialist Medicine. Linköping University, Faculty of Medicine and Health Sciences. Med Univ Innsbruck, Austria.ORCID iD: 0000-0002-2945-2946
Klin Ottakring, Austria.
2025 (German)In: Die Nephrologie, ISSN 2731-7463, Vol. 20, no 6, p. 430-437Article, review/survey (Refereed) Published
Abstract [en]

Nephrology has seen a surge of clinical trials with significant investment by industry to improve patient care in several areas, including diabetes and chronic kidney diseases (CKD) and rare diseases, such as immunoglobulin A (IgA) nephropathy (IgAN). The reason for these investments is in part that nephrologists, agency representatives (especially of the U.S. Food and Drug Administration, FDA) and companies have defined new outcomes of clinical trials. These enable the design and conduct of such clinical trials in a more economical way; i.e., a more manageable number of trial participants and a shorter duration of follow-up. In consequence, the field of nephrology has evolved into a discipline where the speed of development and approval of new interventions is rapidly growing. This article provides an overview of issues with trials conducted in nephrology in the past and outline new surrogate endpoints that have recently been implemented in several fields of nephrology.

Place, publisher, year, edition, pages
Heidelberg: Springer Berlin/Heidelberg, 2025. Vol. 20, no 6, p. 430-437
Keywords [en]
Chronic kidney disease, IgA nephropathy, Kidney replacement therapy, Prognosis, Clinical trials, Clinical trials, IgA nephropathy, Kidney replacement therapy, Prognosis, Clinical trials
National Category
General Medicine
Identifiers
URN: urn:nbn:se:liu:diva-217499DOI: 10.1007/s11560-025-00874-yISI: 001558240700001Scopus ID: 2-s2.0-105013763994OAI: oai:DiVA.org:liu-217499DiVA, id: diva2:1996445
Note

Funding Agencies|University of Innsbruck; Medical University of Innsbruck

Available from: 2025-09-09 Created: 2025-09-09 Last updated: 2026-02-24

Open Access in DiVA

fulltext(332 kB)12 downloads
File information
File name FULLTEXT02.pdfFile size 332 kBChecksum SHA-512
31226820d6402391e54239000fd10b04c279de6d7f38613caab3b692004dbcb0b79e26589215cdbffa5d1ee4979dfa2d9f0d904b2ec2aa0391058b43f360a192
Type fulltextMimetype application/pdf

Other links

Publisher's full textScopus

Authority records

Kronbichler, Andreas

Search in DiVA

By author/editor
Kronbichler, Andreas
By organisation
Division of Diagnostics and Specialist MedicineFaculty of Medicine and Health Sciences
General Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 13 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 127 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf